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Use of quercetin in animal feed: 
effects on the P-gp expression 
and pharmacokinetics of orally 
administrated enrofloxacin in 
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Liping Wang1
Modulation of P-glycoprotein (P-gp, encoded by Mdr1) by xenobiotics plays central role in 
pharmacokinetics of various drugs. Quercetin has a potential to modulate P-gp in rodents, however, 
its effects on P-gp modulation in chicken are still unclear. Herein, study reports role of quercetin in 
modulation of P-gp expression and subsequent effects on the pharmacokinetics of enrofloxacin in 
broilers. Results show that P-gp expression was increased in a dose-dependent manner following 
exposure to quercetin in Caco-2 cells and tissues of chicken. Absorption rate constant and apparent 
permeability coefficient of rhodamine 123 were decreased, reflecting efflux function of P-gp in chicken 
intestine increased by quercetin. Quercetin altered pharmacokinetic of enrofloxacin by decreasing area 
under curve, peak concentration, and time to reach peak concentration and by increasing clearance 
rate. Molecular docking shows quercetin can form favorable interactions with binding pocket of 
chicken xenobiotic receptor (CXR). Results provide convincing evidence that quercetin induced P-gp 
expression in tissues by possible interaction with CXR, and consequently reducing bioavailability of 
orally administered enrofloxacin through restricting its intestinal absorption and liver/kidney clearance 
in broilers. The results can be further extended to guide reasonable use of quercetin to avoid drug-feed 
interaction occurred with co-administered enrofloxacin or other similar antimicrobials.
Quercetin is one of the flavonoids which are natural polyphenolic compounds found in numerous components 
of the human daily diet, including red wine, onions, apples, tea and grapefruit juice1. It exerts a broad range of 
fascinating clinical properties, such as anti-inflammatory2, antineoplastic3, antimicrobial4, antiallergic5 and anti-
viral6 activities. The quercetin is used as a phytogenic additive in chicken feed due to a wide variety of expected 
beneficial effects on growth performance, oxidation stability, egg and meat quality, immune characteristics and 
anti-inflammation7. In addition to those expected beneficial effects of quercetin in chicken feed, it was also 
demonstrated that quercetin plays a role in modulation of the permeability-glycoprotein (P-gp) and its functional 
activity8. P-gp, encoded by multidrug resistance protein 1 (Mdr1) or ATP-binding cassette sub-family B member 
1 (Abcb1) gene, is the main member of ABC transporters responsible for the efflux of numerous xenobiotics9 and 
it plays a central role in absorption, distribution, and excretion of therapeutic agents10,11. It was demonstrated that 
quercetin has a clinical role in drug-drug interaction for transportation and bioavailability of P-gp substrates in 
various mammalian species such as pig11, rat12, rabbit13, and in lamb14. Furthermore, it was reported that querce-
tin induces expression of P-gp in mice15, and human healthy subjects16, while downregulates P-gp expression 
in gastric cancer cells17. These findings suggest that P-gp expression can possibly be regulated by quercetin and 
consequently affect the pharmacokinetics of therapeutic agents. However, considering the reported substantial 
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interspecies differences in P-gp expression, these findings cannot be directly extrapolated from rodents and 
humans to chickens. The research on modulation of P-gp expression and drug efflux by quercetin in chicken is 
thus required.
Enrofloxacin is a frequently used fluoroquinolone in the poultry industry in China for the medication of 
infections caused by bacteria, rickettsiae, and mycoplasmas18. It has been proved that enrofloxacin is the sub-
strate of P-gp in chicken and pigs19,20. Therefore, an important line of P-gp investigations is its pharmacokinetic 
interactions with feed or feed additives and their possible impact on the clinical efficacy of antibiotics. Herein, 
we investigated the effects of quercetin on P-gp expression levels and its functional activity in in vitro and in vivo 
model systems as well as pharmacokinetics interaction of quercetin with enrofloxacin in chicken.
Our results indicate that quercetin could upregulate the expression and activity of the P-gp in Caco-2 cells and 
in different tissues of the broiler, and importantly modulate pharmacokinetics of orally administered enrofloxacin 
in chicken. The current results can be helpful in guiding rational use of additives and drugs in the poultry indus-
try to avoid possible adverse effects.
Results
Effect of quercetin on P-gp expression in Caco-2 cells. Mdr1 mRNA expression levels were quantified 
using RT-PCR following different quercetin concentrations (5 and 25 µM) at different consecutive time points at 
6 h, 12 h and 24 h (Fig. 1). When compared to control, the addition of two different concentrations of quercetin 
had significantly up-regulated the Mdr1 mRNA in Caco-2 cells at all time-points investigated (P < 0.05, P < 0.01), 
except at 6 h after the addition of 5 µM quercetin concentration.
The P-gp protein expression in Caco-2 cells was also examined by Western blotting at the same time points after 
administration of different concentrations of quercetin (Fig. 2A). The expression of the P-gp protein was signifi-
cantly increased (P < 0.05, P < 0.001) at all time-points in quercetin-treated cells vs. untreated cells (Fig. 2B–D). 
The increase in P-gp protein levels was in a good correlation with the increase in mRNA levels at 6, 12 and 24 h, 
except for a 6 h time point after administration of 5 µM quercetin, which is not uncommon observation due to 
various factors that affect transcription rates and protein expression.
Moreover, immunofluorescence staining demonstrated an overexpressed level of P-gp protein in the cell mem-
brane of quercetin-treated Caco-2 cells (Fig. 3D,F), and merely insignificant or negligible P-gp staining was seen 
in non-treated Caco-2 cells (Fig. 3B). For comparison of the immunofluorescence reactivity, the nuclei were 
counterstained with DAPI (Fig. 3A,C and E). The above results evidenced that P-gp protein was highly expressed 
in Caco-2 cells following the addition of quercetin.
Effect of quercetin on Mdr1 mRNA expression in broilers. The expression levels of Mdr1 mRNA 
were evaluated in different tissues of broilers by real-time RT-PCR after quercetin administration at different 
dosages (15 and 60 mg/kg) for 1, 5 and 10 days (Fig. 4). When compared to control, significant up-regulation was 
observed in liver Mdr1 mRNA levels in quercetin-treated groups on all consecutive days. In the kidney, Mdr1 
mRNA expression significantly increased with both doses of quercetin on days 5 and 10 (P < 0.05). In the duode-
num, Mdr1 mRNA expression levels significantly increased with 15 mg/kg concentration of quercetin for 5 and 
10 days of administration, and with 60 mg/kg concentration of quercetin for 10 days of administration (P < 0.05). 
In jejunum, Mdr1 mRNA expression levels were increased with 15 mg/kg quercetin concentration on 5 and 10 
days, while Mdr1 mRNA was also increased with 60 mg/kg dose of quercetin on day 1 (P < 0.05). In ileum, the 
Mdr1 expression levels increased non-significantly in all treatment groups. Amongst all tissues, the highest Mdr1 
mRNA expression was seen in liver followed by kidney, duodenum, jejunum, and ileum.
Evaluation of P-gp function by Rho 123 uptake after quercetin administration in chickens. To 
further evaluate whether up-regulated Mdr1 mRNA expression by quercetin is accompanied by stronger efflux 
function in the small intestine, perfusion model in the jejunum of broilers was chosen for drug-drug interac-
tion study (quercetin-substrate). The jejunum perfusion was evaluated by monitoring Rho 123 concentration 
(control and quercetin-treated samples) vs. time as depicted in Fig. 5. Efflux ratios in the jejunum of broilers 
Figure 1. The effect of quercetin on mdr1 mRNA levels in Caco-2 cells. Each sample was run in triplicate. 
GADPH was used as a reference gene for normalization. Results are represented as mean ± S.E.M and were 
analyzed by one-tailed ANOVA using SPSS 18.0 version followed by a least significant difference (LSD) test 
for individual comparisons. *P < 0.05 and **P < 0.01 between quercetin treated vs. untreated Caco-2 cells at 
different time points.
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Figure 2. Modulation of P-gp expression in Caco-2 cells by quercetin. (A) Immunoblot of human P-gp protein; 
The relative protein expression levels different time points is shown in (B) 6 h, (C) 12 h, and (D) 24 h. Graphical 
bars show mean ± SEM (n = 3) of the P-gp/β-actin band intensities ratios. The experiments were run under 
similar conditions and blots were cropped from different parts of gel and original full-sized images. Samples 
were obtained from the same experiment and blots were processed concurrently.
Figure 3. P-gp expression levels in Caco-2 cell line monitored through immunofluorescence following 24 h 
exposure to quercetin. The nuclei of cells counterstained by DAPI in Caco-2 cells were (A) not treated with 
quercetin (control), and treated with quercetin at (C) 5 µM and (E) 25 µM. Immunofluorescence staining shows 
the P-gp expressions in (B) cells not treated with quercetin (control) and in cells treated with quercetin at (D) 
5 µM and (F) 25 µM. The immunofluorescence staining on the membrane of Caco-2 cells was much stronger in 
quercetin-treated cells as compared to control.
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Figure 4. Expression levels of Mdr1 mRNA in different tissues of broilers detected by real-time RT-PCR 
(n = 5). Comparison of Mdr1 mRNA levels in untreated (control) and quercetin-treated adult healthy broilers 
on different days in (A) liver, (B) kidney, (C) duodenum, (D) jejunum and (E) ileum; β-actin was used as 
housekeeping gene for normalization. Results are represented as mean ± S.E.M and were analyzed by one-tailed 
ANOVA using SPSS 18.0 version followed by a least significant difference (LSD) test for individual comparisons. 
*P < 0.05, **P < 0.01.
Figure 5. Mean Rho 123 concentrations vs. time curves in the jejunum of broilers. Control group I: PBS alone 
administered orally to adult healthy broilers (n = 6); Groups II and III: Co-administration of quercetin via the 
oral route (15 mg/kg, n = 6) and (60 mg/kg, n = 6), respectively. PBS and quercetin were administered for 3 days, 
which was followed by Rho 123 perfusion experiments for all groups. Each point represents the mean ± S.E.M 
of 6 broilers.
www.nature.com/scientificreports/
5SCIeNtIFIC RepoRts |  (2018) 8:4400  | DOI:10.1038/s41598-018-22354-1
after perfusion of Rho 123 were presented in Table 1. When compared to control, results showed an obvious 
increase of Rho 123 concentrations in the perfusion fluid for quercetin-treated broilers. Rho 123 absorption rate 
constant (Ka) was with a downward tendency but non-significantly. However, an apparent permeability coeffi-
cient (Papp) significantly (P < 0.05) decreased in quercetin-treated broilers. The concentrations of quercetin for 
a certain period of time induced the efflux activity of P-gp which correlates to overexpression of Mdr1 mRNA in 
the jejunum.
Pharmacokinetics assessment of enrofloxacin after quercetin administration in chicken. 
Following oral administration, a one-compartment model was found to provide the best fit for concentration-time 
results of enrofloxacin. The plasma concentrations vs. time curves for enrofloxacin are presented in the Fig. 6. 
Pharmacokinetic parameters of enrofloxacin in broilers previous to and following administration of querce-
tin are shown in Table 2. As compared to control group, area under curve (AUC, 17.35 ± 1.04 μg∙h/mL) and 
peak concentration (Cmax, 1.79 ± 0.13 μg/mL) were decreased and drug clearance rate were increased (CL, 
563.45 ± 29.76 mL/h/kg) when high concentration (60 mg/kg) of quercetin was administered (P < 0.05). The 
decrease of time to reach peak concentration (Tmax, 1.40 ± 0.24 and 1.60 ± 0.24 h) was observed when low and 
high concentrations of quercetin were co-administered (P < 0.01, P < 0.05). By administrating both doses of 
Parameters Control
Quercetin 
(15 mg/kg)
Quercetin 
(60 mg/kg)
Ka (min−1) 0.153 ± 0.034 0.089 ± 0.008 0.084 ± 0.017
Papp (cm ∙ min−1) 0.013 ± 0.001 0.0091 ± 0.001* 0.0088 ± 0.001*
Table 1. Transport of Rho123 in jejunum of broilers (mean ± S.E.M, n = 6). *P < 0.05 significant difference 
control vs. treated groups. Ka: drug absorption rate constant; Papp: apparent permeability coefficient.
Figure 6. Mean plasma concentration of enrofloxacin vs. time curves after a single administration of the drug 
(10 mg/kg) without and with co-administration of quercetin at two concentrations (15 and 60 mg/kg). Each 
point represents the mean ± S.E.M of 5 broilers.
Parameters Control Quercetin (15 mg/kg) Quercetin (60 mg/kg)
T1/2 (h) 4.81 ± 1.06 4.94 ± 0.72 4.76 ± 0.56
Tmax (h) 2.75 ± 0.25 1.40 ± 0.24** 1.60 ± 0.24*
Cmax (µg/mL) 2.67 ± 0.30 2.00 ± 0.10 1.79 ± 0.13*
AUC0–24h (µg·h/mL) 23.75 ± 2.03 18.31 ± 1.51 17.35 ± 1.04*
AUC0~∞ (µg·h/mL) 24.69 ± 2.05 19.11 ± 1.34 17.95 ± 0.98*
Vd (mL/kg) 2.83 ± 0.60 3.91 ± 0.75 3.92 ± 0.58
CL (mL/h/kg) 413.17 ± 32.80 534.80 ± 41.21 563.45 ± 29.76*
Table 2. Pharmacokinetic parameters of oral enrofloxacin in broilers (mean ± S.E.M, n = 5). *P < 0.05, 
**P < 0.01 significant difference control vs. treated groups. T1/2: half-life; Tmax: the time to reach peak 
concentration; Cmax: the peak concentration; AUC0–24 h and AUC0~∞: the area under the plasma concentration-
time curve from zero to 24 h and infinity, respectively; Vd: apparent volume of distribution; CL: clearance rate.
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quercetin, the non-significantly rising trends were seen in the apparent volume of distribution (Vd). These results 
suggest that by administrating the quercetin can possibly induce the higher expression level of Mdr1 mRNA in 
healthy broilers resulting in a reduced peak concentration of enrofloxacin in the blood. This assumption supports 
a correlation of observed AUC decrease and Vd increase to reduced oral absorption.
Molecular modelling. In silico analyses were carried out to establish a potential mechanism of action of 
quercetin. The shape and features similarity calculation has shown that quercetin, as anticipated, has high similar-
ity to a range of flavonoids that are known to induce expression of P-gp15 (Table 3). The hybrid score ranges from 
around 1.7 for similarity to chrysin and myricetin, which goes down to 1.24 for the lowest similarity to genistein. 
These results suggest a good overlap in the shape of similar molecules as exemplified by shape complementarily 
between quercetin and myricetin (Fig. 7).
The docking scores support our assumption that quercetin may interact with the same proteins as the other 
P-gp inducers, and in this case, we have focused on the chicken xenophobic receptor (CXR) and chicken vitamin 
D receptor (CVDR) that are known to be involved in the up-regulation of P-gp expression15,21. The calculated 
interaction energies between quercetin and homology models of these two receptors in chicken are very similar 
Name
Molecular similarity to quercetin 
expressed as Hybridscore
Docking scores against protein 
target (kcal/mol)
CXR CVDR
quercetin 2.00 −8.20 −7.80
chrysin 1.70 −8.20 −8.20
myricetin 1.66 −8.00 −7.90
taxifolin 1.50 −8.10 −7.70
cyanidin 1.36 −7.90 −7.50
isoxanthohumol 1.34 −9.70 −9.00
genistein 1.24 −7.80 −7.70
rhodamine123 1.00 −9.80 −9.70
oxycodone 0.98 −8.80 −8.60
morphine 0.90 −8.10 −8.00
dexamethasone 0.86 −8.90 −8.10
amprenavir 0.73 −8.40 −9.40
nelfinavir 0.73 −9.80 −10.20
indinavir 0.71 −9.10 −8.60
saquinavir 0.68 −10.00 −9.80
retinoicacid 0.67 −8.60 −7.80
rifampin 0.65 13.10 13.90
vincristine 0.63 10.50 12.50
ritonavir 0.61 −8.80 −8.70
cyclosporinA 0.42 105.50 120.20
clotrimazole — −10.90 −10.00
phenothiazine — −7.20 −6.50
Table 3. The molecular similarity and docking scores of quercetin obtained by calculating shape and features 
similarity of quercetin to known P-gp inducers and by predicting binding affinities to the chicken xenophobic 
receptor (CXR) and chicken vitamin D receptor (CVDR).
Figure 7. The molecular similarity of quercetin (green thin lines) to P-gp inducers (thick grey lines) (A) 
myricetin, (B) rhodamine 123 and (C) dexamethasone. All molecules are shown in stick representation colored 
according to CPK scheme except for quercetin carbon atoms colored in green. Hydrogen atoms are not shown 
for clarity.
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to docking scores of most P-gp inducers that can bind to both proteins (Table 3). The docking score of quercetin 
indicates less favorable interactions with these proteins when compared to molecules that are larger and can form 
more interactions with protein binding sites (e.g. isoxanthohumol, nelfinavir, saquinavir, clotrimazole). However, 
the quercetin can fit into a binding pocket and form favorable interactions with both proteins as both flavonoid 
and non-flavonoid based P-gp inducers (Fig. 8). The interaction energy between quercetin and CXR is more 
favorable when compared to the interaction energy between quercetin and CVDR.
Discussion
Quercetin is found in a broad range of fruits, vegetables, and beverages and may lead to possible pharmacoepi-
genetic interactions as previously indicated22. As one of the ingredients in poultry feed that comes from plants, 
quercetin may affect the bioavailability or the withdrawal period of P-gp substrates in chickens, which is of high 
practical relevance from therapeutic efficacy and food safety point of the view. The results of our study suggest 
that quercetin can alter the expression levels and functional activity of P-gp, and therefore it is involved in natural 
product-drug interaction when simultaneously administered with P-gp substrate enrofloxacin. To the best of our 
knowledge, this is the first report to demonstrate that quercetin could up-regulate Mdr1 expression and its efflux 
function in chicken.
Figure 8. Molecular docking solutions against CXR and CVDR targets obtained for quercetin (green thin lines) 
and p-gp inducers (thick grey lines). Quercetin docking poses are compared to docking poses of myricetin, 
rhodamine 123 and dexamethasone in the active site of the CXR (A–C) and CVDR (D–F). Active sites are 
delineated by the hydrophobic surface and surrounding residues which are labelled and represented as thin grey 
lines. Hydrogen atoms are not shown for clarity.
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No suitable cell-based model systems (passage cells) or effective antibody of chicken P-gp pose one of the 
most difficult obstacles for studying the chicken P-gp and effects of small molecules on its function. Caco-2, a 
human colorectal adenocarcinoma cell line, has been accredited by the US Food and Drug Administration (FDA) 
for in vitro transport and P-gp expression studies22,23. In this study, Caco-2 cell line was firstly selected as an in 
vitro model for validating the effects of quercetin on P-gp expression at the transcriptional and translational level. 
These results established that quercetin is a potential inducer of P-gp mRNA/protein, which was consistent with 
some previous reports about flavonoids inducing the P-gp expression15,24,25. Therefore, the in vivo tests in chicken 
were undertaken. All results of this study corroborated that quercetin can upregulate the Mdr1 expression in 
chicken in line with Caco-2 cell and previous studies in human, mice, and pig12,15,16. Though the expression level 
of P-gp in protein level was not measured due to the lack of relevant chicken antibody, the increased efflux activity 
of chicken intestinal P-gp was further established by in situ experiment using Rho 123 as probe substrate. In this 
study, the expression level of P-gp mRNA was found to be highest in jejunum; therefore, in situ perfusion was 
performed in the jejunum. This was also in agreement with experiments and observations in previously published 
studies, where jejunum was chosen as a model for intestinal perfusion experiments26,27.
The data also confirmed that decrease in Cmax and AUC0–24 h of enrofloxacin in quercetin-treated broilers 
corresponded to Mdr1 mRNA overexpression. It is likely that the increased Mdr1 expression in small intestine, 
liver, and kidney of healthy broilers can reduce the absorption of orally administered enrofloxacin and it facil-
itated the clearance from bile and urine, thus lowering the systemic concentrations. The modulation of Mdr1 
expression caused noteworthy changes in the pharmacokinetic profiles of enrofloxacin, which is coinciding with 
cyclosporine and talinolol pharmacokinetics profile due to quercetin modulation of P-gp in pig and rats and 
human, respectively12,16. The above observations appear to be contradictory to one of the studies in rat, where 
the increase of paclitaxel bioavailability was observed when the low doses of quercetin (2, 10, 20 mg/kg) were 
administered for three days8. That was in line with the general expectation that inhibition of the P-gp leads to the 
increased drug bioavailability. However, it was not experimentally investigated whether P-gp was overexpressed 
or inhibited. In our study, low and high doses of quercetin (15 and 60 mg/kg) were administered for 1, 5, and 10 
days. Albeit, the high concentrations increased the expression of P-gp and reduced the bioavailability of enroflox-
acin, administration of lower concentration of quercetin (15 mg/kg) for a short period (1 day) does not induce 
P-gp overexpression but inhibits the P-gp, thus having the effect on enrofloxacin concentration in chicken that is 
similar to the effect observed in rat.
The reported studies regarding pharmacodynamics and pharmacokinetics properties of fluoroquinolones sug-
gested that critical breakpoints deciding the therapeutic efficacy of these drugs are defined by Cmax/MIC ratios 
≥10 and AUC/MIC ratios ≥10028,29. The MIC of enrofloxacin reported being 2 µg∙mL−1 against field isolates of 
Escherichia coli30 and Mycoplasma spp.31 in chicken. By using 2 µg.mL−1, the Cmax/MIC ratios observed after a 
single orally administered dose of enrofloxacin were 1.335, 1, 0.895 for two quercetin groups (15 and 60 mg/kg), 
and for a control, respectively. The AUC/MIC ratios were 11.875, 9.1 and 8.675, respectively. As compared with 
control, the Cmax/MIC ratios decreased by 24.81% and 32.95% after treatment with quercetin (15 and 60 mg/
kg), respectively, while AUC/MIC ratios of enrofloxacin decreased by 22.90% and 26.94% for these two groups. 
Taken together, P-gp overexpression by quercetin reduced the bioavailability of enrofloxacin and its plasma con-
centration. This is a reason for serious concern as lower antibiotic concentration may result in a possible loss of 
the enrofloxacin effectiveness against poultry pathogens. Importantly, additional research is required to evaluate 
the use of other antimicrobials and their interaction with quercetin mediated by P-gp efflux.
It is reported that various flavonoids including quercetin regulated the P-gp expression through pregnane 
X receptor (PXR) and constitutive androstane receptor (CAR)32 in human, and recently, it is also reported that 
quercetin upregulated the P-gp through vitamin D receptor (VDR) dependent pathway in Caco-2 cells25. It was 
previously demonstrated that the quercetin has potential to interact with multiple targets via judicious analysis 
using reverse docking methods33. In this study, it is postulated that quercetin can regulate the Mdr1 expres-
sion through a chicken xenobiotic receptor (CXR), as well as through chicken vitamin D receptor34 (CVDR). 
Findings from molecular docking analysis show that quercetin has similar structural features to many P-gp 
inducers (Fig. 7) and moreover, it can favorably interact with active sites in ligand binding domains of CXR and 
CVDR. The interaction energy between quercetin and CXR is more favorable when compared to the interaction 
energy with CVDR. These analyses strongly support our assumption that quercetin regulated the P-gp expression 
through CXR signaling pathways.
In conclusion, we investigated the quercetin modulated Mdr1 expression in Caco-2 cells and in chicken. This 
is the first report demonstrated that quercetin increased the Mdr1 expression in the tissues (liver, kidney, duode-
num, and jejunum) of chickens. Consequently, this resulted in the Rho 123 uptake modulation and affected the 
pharmacokinetics of enrofloxacin in broilers. These presented findings have strong implication that quercetin 
contained in animal feed may have an effect on the bioavailability of numerous xenobiotics including antimicro-
bials, which are P-gp substrates, via overexpression of Mdr1 and efflux by P-gp.
Materials and Methods
Reagents/drugs, cells, and cell culture. Dulbecco’s Modified Eagle Medium (DMEM), fetal bovine 
serum (FBS) and Trypsin-EDTA obtained from Gibco Company. Quercetin was obtained from Shanghai reagent 
industry (China). China Institute of Veterinary Drug Control (Beijing, China) donated the enrofloxacin hydro-
chloride drug. Rhodamine 123 (Rho 123) and MTT were purchased from Sigma (St. Louis, MO, USA). Caco-2 
cell line was bought from Cellular Resource Centre of Shanghai Institute for Biological Science, Chinese Academy 
of Sciences (CAS). The remaining compounds utilized were standard quality from a local vendor.
Caco-2 cell line were propagated on constant cultural conditions such as 37 °C temperature, 5% CO2 and 95% 
humidity in incubator; and high glucose DMEM added with 10% FBS, penicillin (100 U/mL) and streptomycin 
(100 μg/mL). 0.02% EDTA- 0.25% trypsin was used for trypsinization.
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Animals. Arbor Acres (AA) chickens were bought from a commercial hatchery (Nanjing, Jiangsu China). 
Total 100 one-day-old AA broilers were managed under recommended circumstances of light and temperature. 
Feed (no antimicrobials and anticoccidials) and water were given ad libitum. All birds were fed according to the 
breeding standards approved by National Research Council (NRC). Birds use and caring protocols were approved 
by the Science and Technology Agency of Jiangsu province. The approval ID is SYXK (SU) 2010–0005. The pro-
tocol of the study was conducted in accordance with guidelines of the Science and Technology Agency of Jiangsu 
Province and Nanjing Agricultural University. All efforts were made to minimize animal’s suffering. Prior to 
beginning the trial at adult age, all broilers were inspected free from colibacillosis.
The expression level of P-gp in Caco-2 cells. When the Caco-2 cells reached maximum confluence, 
they were harvested and plated for drug treatments. 5 × 104 cells were seeded in the 24-well plates and propagated 
for 24 h after that DMEM was removed when cells reached up to the confluence of 80%. 0, 5 and 25 µM concen-
trations of quercetin were applied at consecutive timings (6, 12 and 24 h) for quantification of mRNA level. For 
detection of protein expression, the same number of cells grown on 15 mm slides and same quercetin treatments 
were applied for 24 h. Each sample repeated triplicate and 0 served as control.
The expression level of mRNA for Mdr1 was measured by qRT-PCR. Whole RNA was isolated from Caco-2 
cells by Trizol method (Takara, Tokyo, Japan) following the company’s recommendations. Samples were treated 
with 100 U DNase I (RNase-Free, Takara, and Tokyo, Japan) at 37 °C for 30 min to make sure that the entire RNA 
was free from DNA contamination. Afterward, the whole RNA counted through spectrophotometer (ND-1000, 
Rockland, DE, USA). Ratios of optical density values (260/280 nm) of the entire preparations were ranges from 
1.8 and 2.0. The integrities of each RNA sample were verified by electrophoresis on a 1.4% agarose gel. cDNAs 
were made and RT-PCR was carried out. Negative controls involved the omission of RNA from the RT reactions 
and amplification with specific primer sets to verify without DNA contamination. Specific primers for mdr1 and 
GAPDH in human were designed as earlier reported35 and commercially manufactured for RT-PCR evaluation. 
Human GADPH was selected as a housekeeping gene for normalization. The PCR products were sequenced 
to confirm the uniqueness of the amplicons. 2−ΔΔCt method36 was employed for data analysis obtained from 
RT-PCR.
P-gp relative expression was measured by western blotting with minor amendments37. Cell protein was sep-
arated utilizing protein extraction kit (Beyotime, Haimen, China). In brief, the same quantity of membrane pro-
teins (20 μg per lane) was used during SDS-PAGE and after that transferring was done on PVDF membranes 
(BioRad, USA). The membranes were blocked with 5% skim milk powder and incubated with primary antibod-
ies e.g: Mdr-1 (Santa Cruz, Germany, 1:200) and β-actin (TransGen, China, 1: 5,000) at 4 °C overnight. Then 
washing of membranes was done 3 times with PBST for 15 min. Afterward, HRP-labeled secondary antibody 
(goat anti-mouse IgG,1:5000, Boster, Wuhan, China) was applied for 1 h at 37 °C, and same washing steps were 
followed for 5 times. The ECL kit was used via visualizing the bands (Vazyme, China) and image were examined 
using chemiluminescence imaging system (5200-Tanon, China). The statistical analysis was done via bioinfor-
matics software Image-Pro Plus 4.1. The software-based data (densitometric values) were employed to estimate 
the expression level of P-gp.
The procedure of immunofluorescence staining was executed as depicted formerly with a minor alteration38. 
The 4% paraformaldehyde was used for fixing of cells and after that PBC buffer including 3% BSA was employed 
for blocking up to 1 h. The primary antibody (1: 200, rabbit anti-P-gp) applied for overnight at 4 °C, and after-
ward, cells were again applied with secondary antibody (1:200, goat anti-rabbit IgG-FITC, Fermentas, Hanover, 
MD, USA) for 1 h at 37 °C. Finally, visualization was done through an immune reaction using DAB stain.
The Mdr1 mRNA expression in Chicken. 35 adult healthy birds (42-days-old) averagely weighted 
2 ± 0.13 kg were selected for RT-PCR and divided into seven groups (5 birds per group). Group-I remained as 
a control without any treatment. The quercetin was administered orally to II, III, and IV groups with a dose rate 
of 15 mg/kg b.w. and to V, VI, and VII groups with a dose rate of 60 mg/kg b.w. for 1, 5 and 10 days, respectively.
The randomly chosen birds were sacrificed through decapitation after completion of the treatment period 
(1, 5, and 10 days), and the tissue samples (liver, kidney, small intestine) were taken from adult healthy birds. 
The entire set of samples was kept at −80 °C until RT-PCR evaluation was carried out. The expression levels of 
mRNA for Mdr1 in liver, kidney and small intestine of broilers were measured via using qRT-PCR. All RT-PCR 
experiments were carried out under conditions similar to those carried out in Caco-2 cells. Specific primers used 
for Mdr1 and β-actin in broilers were designed as earlier reported39 and commercially manufactured for RT-PCR 
evaluation. Chicken β-actin was selected as a housekeeping gene for normalization. The PCR products were 
sequenced to confirm the uniqueness of the amplicons. 2 −ΔΔCt method was used for analysis of the data obtained 
from RT-PCR.
In situ perfusion of Rho 123 in quercetin-treated chicken and HPLC assay for Rho 123. Eighteen 
adult healthy broilers (42-days-old) with an average weight of 2 ± 0.13 kg were selected and separated into three 
groups (6 birds per group). PBS was given to Group-I which designated as the control. Groups II and III were 
continuously treated with quercetin orally for 5 days with doses of 15 and 60 mg/kg b.w., respectively. The exper-
iment for perfusion model of jejunum was done as previously described with some modifications40. Birds fasted 
for 12 h and had a free access to water. All birds were anesthetized with 20% solution of urethane administered 
intravenously. Laparoscopy was performed by incision of the abdomen up to 3–4 cm and jejunum was exposed 
for a length of 10 cm. The exposed part was wrapped with a cotton pad soaked in normal saline and afterward 
with aluminum foil to avoid evaporation of fluids. The upper end of the lumen was catheterized with an inflow 
cannula, which was joined to perfusion system. The lower end of the jejunum was also catheterized with an out-
flow cannula to collect intestinal effluents serially. The lumen of jejunum was flushed with K-R buffer solution 
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pre-warmed to 40 °C at a constant flow speed of 0.2 ml/min for 30 min until the clear solution emerged. Then Rho 
123 (1.5 µg /L in K-R buffer) solution was perfused at a stable flow speed of 10 ml/min for 2 min for equilibration 
of the intestinal segment, and then it was again perfused after every 10 min at a constant flow speed of 0.2 ml/min. 
After that, blank solution (K-R buffer) was perfused at a constant flow speed of 5 ml/min for 5 min. The intestinal 
perfusate samples were taken every ten minutes for a period of 100 min in pre-weighed 5-ml glass vials and were 
stored at −20 °C in the dark. At the final stage of the trial, the length of the intestinal segment was measured as 
well as the radius of the loop (cm). The broilers were euthanized at the end of the experiments.
The concentrations of Rho123 in perfusion samples were determined using Agilent 1200 HPLC system. The 
perfusates were thawed out at room temperature and centrifuged at 12 000 g for 20 min. The supernatants were sepa-
rated according to concentrations of Rho 123 standard solution used in perfusion experiments (0.15, 0.3, 0.75, 1.5, 3 
and 7.5 μg/L). Five samples were prepared for each concentration. The sample (0.1 ml) was added to acetonitrile then 
through centrifugal force organic and water phases were separated and transferred into tubes. The organic phase was 
treated with nitrogen stream until dried and the residue was re-suspended with mobile phase solution. 10 µl of the 
mixture was injected into the HPLC system. The mobile phase was composed up of 0.1 M phosphoric acid (pH was 
adjusted to 3 with triethylamine)/acetonitrile (84:16, v/v). The perfusion samples contents were analysed using a 
Waters e2695 HPLC system (Waters, Japan) and Kromasil C18 HPLC Columns (5 μm, 25 cm × 4.6 mm). The speed 
of the mobile phase was adjusted up to 0.8 ml/min. Ultraviolet absorbance was recorded at 507 and 572 nm.
The apparent permeability coefficient (Papp) and absorption rate constant (Ka) of Rho123 were quantified 
using given equations: (1) Ka = (1 − Cout Qout/Cin Qin)Q/V, (2) Papp = −Qin (Cout Qout/Cin Qin)/2πrl, where, Qin/
Qout- intestinal perfusate input and output volume (mL), Cin and Cout- mass concentrations of enteric importer 
and exporter perfusate (μg ∙ mL−1), Q- perfusion rate (0.2 mL ∙ min−1), V- volume of bowel perfusion and 2πrl- 
area of the mass transfer surface (cm2).
Experimental model for pharmacokinetic evaluation of enrofloxacin in broilers. Pilot pharmacoki-
netic studies with five chicken in a group were designed and conducted according to previous studies19,41. Further to 
promising results of the pilot study fifteen adult healthy chickens (42-days-old) averagely weighted 2 ± 0.13 kg were 
randomly separated into 3 groups for the full study. Group I broilers were given enrofloxacin orally with a single dose 
of 10 mg/kg b.w. and designated as the control. Groups II and III were treated with quercetin (15 and 60 mg/kg b.w., 
respectively) for 5 days, and followed by a single oral administration of enrofloxacin (10 mg/kg b.w.).
The enrofloxacin was orally administered with the help of gavage and drug concentrations in the blood were 
measured over 24 h period. The sampling time points were chosen based evaluate drug concentrations during 
drug absorption phase (2~3 sampling points), equilibrium phase (at least 3 sampling points near peak concentra-
tion), and the elimination phase (4~6 sampling points), as well as taking into account that whole sampling time 
should cover a period until drug concentration in blood drops to 1/10 of Cmax. For HPLC determination blood 
samples were taken into anticoagulated tubes (heparin) from all groups after 30 min post dosage regimen of enro-
floxacin at 0.083, 0.25, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12 and 24 h. The samples were transported to the laboratory 
on ice boxes and centrifuged at 1500 g for 10 min. The plasma was separated and preserved at −80 °C prior to 
high-performance liquid chromatography calibration.
HPLC assay for detection of enrofloxacin in plasma of broilers. The enrofloxacin from plasma was 
quantified via Agilent-1200 HPLC system as previously reported with a few amendments42. Briefly, the blood 
samples were thawed at room temperature and centrifuged at 2 000 g for 5 min, the supernatant (0.5 ml) was 
added to acetonitrile and through centrifugal force organic and water phases were separated and transferred 
into tubes. The organic phase was treated with nitrogen stream until dried and the residue was re-suspended 
with a mobile phase solution. 20 µl of the mixture was introduced into the HPLC column. The mobile phase was 
composed up of 0.1 M phosphoric acid (pH was adjusted to 3 with triethylamine)/acetonitrile (84:16, v/v). The 
enrofloxacin concentration was measured using a Waters e2695 HPLC system (Waters, Japan) with Kromasil 
C18 HPLC Columns (5 μm, 25 cm × 4.6 mm). The flow speed of the mobile phase was adjusted up to 1.0 ml/min. 
Ultraviolet absorbance was calibrated at 278 nm.
Pharmacokinetic analysis. The practical pharmacokinetic 3p97 software (Version97, Chinese 
Pharmacologic Association, Beijing, China) was used to calculate pharmacokinetic parameters for each indi-
vidual set of data. The Akaike’s Information Criterion was applied which is the best fit for a one compartment 
model43. All calculations of the area under the concentration-time curve (AUC0–24 h) were done according to the 
linear trapezoidal method.
Molecular modelling. Structures of quercetin and known P-gp inducers (myricetin, taxifolin, isoxanthohu-
mol, genistein, chrysin, cyanidin, amprenavir, clotrimazole, dexamethasone, indinavir, morphine, nelfinavir, phe-
nothiazine, retinoic acid, rifampin, ritonavir, saquinavir, oxycodone, cyclosporin A, vincristine and rhodamine 
123) were collated as canonical SMILES string from PubChem database44. Initial three-dimensional models of 
all small molecules were generated from these SMILES strings using Avogadro molecular modelling software 
version 1.2.045. Furthermore, molecules were protonated at pH 7.4 and the lowest energy conformations were 
calculated using Avogadro and MMFF94 force field. The final structures were saved in a mol2 file format.
The GenPept database was used to retrieve sequences of the chicken xenobiotic receptor (CXR) and chicken 
vitamin D receptors (CVDR); their accession numbers were AAG18374 and AAB62579, respectively. Their 
sequences in the fasta file format were submitted to using I-TASSER homology modelling server46 to obtain 
three-dimensional structures. The top solutions were used to carry out further molecular modelling to prepare 
protein structures for molecular docking. The top identified structural analogue for both structures was the reti-
noid X receptor (RXR) alpha found in the PDB entry 4NQA, complexed with a DNA and a molecule PDB id 
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965 bound in the ligand binding domain. To ensure that the active sites in the ligand binding domains of both 
CXR and CVDR are not sterically hindered as a result of homology modelling, Maestro Graphic User Interface 
v2016–2 was used to superimpose both homology models onto the 4NQA structure. The ligand 965 was copied 
into the binding sites of CXR and CVDR. The steric clashes were initially removed manually by adjusting the 
position of the phenylalanine ring that was protruding into binding sites to prepare the complexed structures for 
follow-up molecular dynamics simulation. Both structures were prepared using Protein Preparation wizard by 
adding all hydrogen atoms and setting the protonation states of all ionizable groups in the protein for pH 747. The 
molecular simulations were performed with Desmond and OPLS2005 force field. All models were fully solvated 
using an explicit solvent (SPC water model) with the box size 10 Å larger than the size of a protein in all directions 
using System Builder. The systems were automatically neutralized by addition of an adequate number of relevant 
ions. Each system was minimized until the norm of the energy gradient was <0.1 kcal/mol. Furthermore, CXR 
and CVDR models, with their backbone fixed, were simulated for 1 ns at 300 K under constant pressure and tem-
perature (NPT) conditions. Final structures of all models were used for further computational studies.
Molecular similarity calculations between quercetin and other P-gp inducers were calculated using SHAFTS 
software48 and its default settings. AutoDock Vina software49 implemented in VegaZZ scripting environment50 
was used for docking of quercetin and all P-gp inducers into the active sites of both CXR and CVDR. The binding 
site, with the size of 18 Å x 18 Å x 18 Å, was positioned in the geometrical center of the bound 965 ligands that was 
removed from the structure prior to docking. Exhaustiveness was set to 20, and the top nine favorable binding 
modes were calculated for each molecule. All images were generated using Biovia Discovery Studio 2016.
Data analysis. Whole results were presented as means ± S.E.M. and scrutinized through one-tailed ANOVA 
employing SPSS 18.0 version pursued via a least-significant difference (LSD) for individual comparisons. The 
mRNA levels were presented as the fold change relative to the mean levels of each group. Further data were eval-
uated through student t-test for individual samples. The significance point adjusted to P < 0.05.
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